TFF Pharmaceuticals

OverviewSuggest Edit

TFF Pharmaceuticals is a biopharmaceutical company focused on developing drug products based on the Thin Film Freezing (TFF) technology platform. It develops inhalation drug products to treat chronic respiratory diseases and lung conditions. The company generates dry powder inhaler version of drugs.
TypePublic
Founded2018
HQAustin, TX, US
Websitetffpharma.com

Latest Updates

Employees (est.) (Dec 2019)4(-42%)
Share Price (Aug 2021)$8.3(-1%)
Cybersecurity ratingAMore

Key People/Management at TFF Pharmaceuticals

Brian Windsor

Brian Windsor

Director & CSO
Glenn Mattes

Glenn Mattes

President, Chief Executive Officer and Director
Kirk Coleman

Kirk Coleman

Chief Financial Officer
Aaron Fletcher

Aaron Fletcher

Chairman of the Board
Stephen Rocamboli

Stephen Rocamboli

Director
Robert S. Mills

Robert S. Mills

Director
Show more

TFF Pharmaceuticals Office Locations

TFF Pharmaceuticals has an office in Austin
Austin, TX, US (HQ)
2600 Vía Fortuna #360
Show all (1)

TFF Pharmaceuticals Financials and Metrics

TFF Pharmaceuticals Revenue

USD

Net income (FY, 2020)

(18.6m)

EBIT (FY, 2020)

(18.7m)

Market capitalization (3-Aug-2021)

210.0m

Closing stock price (3-Aug-2021)

8.3

Cash (31-Dec-2020)

35.3m
TFF Pharmaceuticals's current market capitalization is $210 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

3.0m3.2m8.0m

R&D expense

848.8k8.8m10.7m

Operating expense total

3.9m12.0m18.7m

EBIT

(3.9m)(12.0m)(18.7m)
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

465.9k531.6k889.5k300.6k1.6m1.3m2.3m

R&D expense

140.2k1.7m1.3m2.6m2.2m2.6m2.8m

Operating expense total

606.1k2.2m2.2m2.9m3.9m3.8m5.1m

EBIT

(606.1k)(2.2m)(2.2m)(2.9m)(3.9m)(3.8m)(5.1m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

10.3m28.1m35.3m

Prepaid Expenses

12.1k1.1m2.3m

Current Assets

10.3m29.2m37.6m

PP&E

1.1m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

13.6m10.6m25.7m21.9m41.6m

Prepaid Expenses

27.1k20.3k859.1k610.4k595.0k

Current Assets

13.7m10.6m26.6m22.5m42.2m

PP&E

945.4k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(3.8m)(11.9m)(18.6m)

Accounts Payable

398.2k12.4k862.7k

Cash From Operating Activities

(2.1m)(11.2m)(16.6m)

Purchases of PP&E

(1.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.4m)(3.0m)(2.2m)(4.4m)(7.2m)(3.8m)(7.6m)(12.7m)

Accounts Payable

664.2k426.8k(25.7k)(60.8k)181.3k796.2k274.3k501.9k

Cash From Operating Activities

(562.2k)(1.3m)(2.1m)(3.8m)(6.9m)(2.4m)(6.1m)(10.4m)

Purchases of PP&E

(293.2k)
Show all financial metrics

TFF Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

TFF Pharmaceuticals Online and Social Media Presence

Embed Graph

TFF Pharmaceuticals News and Updates

TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021

Company conference call and webcast at 4:30 PM EDT Company conference call and webcast at 4:30 PM EDT

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

AUSTIN, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that its Pres…

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder

Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels Anticipate Additional Safety Data in 3Q 2021 Initiation of Lung Transplant Study Expected in 2H 2021

Augmenta Bioworks and TFF Pharmaceuticals Announce Selection of Lead Monoclonal Antibody Candidate AUG-3387 for Clinical Development Against COVID-19

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants

TFF Pharmaceuticals Hosting Key Opinion Leader Perspectives on Thin Film Freezing Applications

Focus on TFF Tacrolimus for Lung Transplant and TFF in Vaccine Technology
Show more

TFF Pharmaceuticals Blogs

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update Content Import Thu, 05/13/2021 - 16:00 TFF Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update May 13, 2021 at 4:00 PM EDT This …

TFF Pharmaceuticals to Hold First Quarter 2021 Financial and Business Results Conference Call on May 13, 2021

Company conference call and webcast at 4:30 PM EDT AUSTIN, Texas --(BUSINESS WIRE)--May 4, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF)

TFF Pharmaceuticals Awarded Contract under DARPA’s Next-Generation Personalized Protective Biosystems Program for U.S. Warfighters

Company’s Thin Film Freezing platform to be developed for use in rapidly neutralizing chemical and biological threats at vulnerable tissue barriers to increase soldier protection and decrease operational burden AUSTIN, Texas --(BUSINESS WIRE)--Apr. 13, 2021-- TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals Prices Offering of Common Stock

TFF Pharmaceuticals Prices Offering of Common Stock Content Import Fri, 03/26/2021 - 08:30 TFF Pharmaceuticals Prices Offering of Common Stock March 26, 2021 at 8:30 AM EDT This release is a backfill from a News Wire General AUSTI…

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results Content Import Wed, 03/10/2021 - 16:00 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results March 10, 2021 at 4:00 PM EST This …

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Feasibility work underway to determine the compatibility of NeuroRx’s ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF’s Thin-Film Freezing technology Dry powder inhalation technology has the potential to deliver ZYESAMI directly to the lungs RADNOR, Pa.
Show more

TFF Pharmaceuticals Frequently Asked Questions

  • When was TFF Pharmaceuticals founded?

    TFF Pharmaceuticals was founded in 2018.

  • Who are TFF Pharmaceuticals key executives?

    TFF Pharmaceuticals's key executives are Brian Windsor, Glenn Mattes and Kirk Coleman.

  • How many employees does TFF Pharmaceuticals have?

    TFF Pharmaceuticals has 4 employees.

  • Who are TFF Pharmaceuticals competitors?

    Competitors of TFF Pharmaceuticals include Nuvaira, Gentex Pharma and Lung Therapeutics.

  • Where is TFF Pharmaceuticals headquarters?

    TFF Pharmaceuticals headquarters is located at 2600 Vía Fortuna #360, Austin.

  • Where are TFF Pharmaceuticals offices?

    TFF Pharmaceuticals has an office in Austin.

  • How many offices does TFF Pharmaceuticals have?

    TFF Pharmaceuticals has 1 office.